Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 15, 2026

Walmart earnings, spending data, and more AI disruptions: What to watch this week

View original at finance.yahoo.com
Walmart earnings, spending data, and more AI disruptions: What to watch this week AI turbulence was the dominant theme in markets last week, with software, real estate, financial services, and logistics stocks all facing selling pressure on worries about the scale of AI-related disruption to their businesses…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The categories that surprised to the upside in CPI — non-vehicle goods and non-shelter services — are the ones that matter most for inflation persistence

    80% confidence

  • Every rose has its thorn - economic data was not without flaws

    80% confidence

  • The AI disruption-led selloff in February has been driven by the legitimate belief that AI-driven change is coming faster not only to software, but to many other sectors

    80% confidence

  • The glaring theme underneath the surface for not just Tech, but for every corner of the market right now is an aggressive shoot first ask questions later for any area of the market that has an AI headline

    80% confidence

  • The timing of AI disruption remains indeterminate, and the fog of uncertainty is unlikely to dissipate quickly

    80% confidence

  • This environment of relatively strong growth, juiced by higher tax refunds from the One Big Beautiful Bill Act, an improving job market and a continued trend of lower inflation will keep interest rates in a steady range as we await Kevin Warsh's fresh perspective at the Fed

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com